BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002168
- Locations
- ๐บ๐ธ
Univ of Nebraska, Omaha, Nebraska, United States
๐บ๐ธAnderson Clinical Research, Washington, District of Columbia, United States
๐ต๐ทHosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002041
- Locations
- ๐บ๐ธ
Bristol - Myers Squibb Co, Princeton, New Jersey, United States
A Study of Lobucavir in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00002352
- Locations
- ๐บ๐ธ
San Francisco Veterans Adm Med Cntr, San Francisco, California, United States
๐บ๐ธUniv of Minnesota, Minneapolis, Minnesota, United States
๐บ๐ธMount Zion Med Ctr / UCSF, San Francisco, California, United States
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002293
- Locations
- ๐บ๐ธ
Birmingham Veterans Administration Med Ctr / Univ of Alabama, Birmingham, Alabama, United States
๐บ๐ธBristol - Myers Squibb Co, Princeton, New Jersey, United States
A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002300
- Locations
- ๐บ๐ธ
George Washington Univ Med Ctr, Washington, District of Columbia, United States
๐บ๐ธDenver Public Health Dept, Denver, Colorado, United States
๐บ๐ธDr Stephen J Gabin Jr, Los Angeles, California, United States
The Safety and Effectiveness of Megace in HIV-Infected Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00002345
- Locations
- ๐บ๐ธ
Yale Univ Med School, New Haven, Connecticut, United States
๐บ๐ธGeorgetown Univ Med Ctr, Washington, District of Columbia, United States
๐บ๐ธUniv of California - Davis Med Ctr / CARES, Sacramento, California, United States
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002261
- Locations
- ๐บ๐ธ
Bristol - Myers Squibb Co, Wallingford, Connecticut, United States
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-08-16
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002028
- Locations
- ๐บ๐ธ
Bristol - Myers Squibb Co, Princeton, New Jersey, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002420
- Locations
- ๐บ๐ธ
Pacific Oaks Med Group, Beverly Hills, California, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002418
- Locations
- ๐บ๐ธ
Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
๐บ๐ธBrown Univ School of Medicine, Providence, Rhode Island, United States
๐บ๐ธAIDS Research Consortium of Atlanta, Atlanta, Georgia, United States